Eui-Chong Kim

doi:10.3947/ic.2008.40.1.49

Journal List > Infect Chemother > v.40(1) > 1075442

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim: In Vitro Susceptibility of piperacillin/tazobactam Against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae

NOTE

Infection and Chemotherapy

Infection and Chemotherapy 2008; 40(1): 49-51.

Published online: 29 February 2008

DOI: https://doi.org/10.3947/ic.2008.40.1.49

In Vitro Susceptibility of piperacillin/tazobactam Against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae

Eui-Chong Kim, M.D.

Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea.

Correspondence: Eui-Chong Kim, M.D. Department of Laboratory Medicine, Seoul National University Hospital 101 Daehangno Jongnogu, Seoul 110-744, Korea. Tel:+82-2-2072-3500, Fax:+82-2-764-6542, euichong@snu.ac.kr

Received 30 August 2007 Accepted 13 February 2008

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Minimal inhibitory concentrations (MIC) of piperacillin/tazobactam were determined on 20 clinical isolates of extended-spectrum β-lactamase (ESBL)-producing E. coli and 30 isolates of ESBL- producing Klebsiella pneumoniae. MIC₅₀ and MIC₉₀ for ESBL-producing E. coli were 8/4 µg/ml and 256/4 µg/mL, respectively. MIC₅₀ and MIC₉₀ for ESBL-producing K. pneumoniae were 8/4 µg/mL and > 512/4 µg/mL, respectively. The susceptibilities of ESBL-producing E. coli and K. pneumoniae to piperacillin/tazobactam were 80% and 60%, respectively. Of 20 ESBL-producing E. coli strains, 11 (55%) were TEM-and CTX-M-positive, and SHV-negative. Of 30 ESBL-producing K. pneumoniae strains, ten (33%) were PCR positive for SHV and negative for TEM and CTX-M.

Keywords: Piperacillin/tazobactam, ESBL-producing E. coli, ESBL-producing K. pneumoniae

Figures and Tables

Fig. 1

MIC cumulative percentage curves of piperacillin/tazobactam. Abbreviations: ECO, E. coli, KPN, K. pneumoniae.

Table 1

Number of Isolates of Extended-spectrum β-lactamase-producing E. coli and K. pneumoniae According to the ESBL Gene Types

References

1. Gavin PJ, Suseno MT, Thomson RB Jr, Gaydos JM, Pierson CL, Halstead DC, Aslanzadeh J, Brecher S, Rotstein C, Brossette SE, Peterson LR. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother. 2006. 50:2244–2247.

2. Lee J, Pai H, Kim YK, Kim NH, Eun BW, Kang HJ, Park KH, Choi EH, Shin HY, Kim EC, Lee HJ, Ahn HS. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy. J Antimicrob Chemother. 2007. 60:629–637.

3. Shin HJ, Jang YS, Seo MR, Pai HJ, Ahn MJ, Lee YY, Choi TY. Impact of Piperacillin/Tazobactam Use to Intestinal Colonization of Extended-spectrum-lactamase Producing Escherichia coli and Klebsiella pneumoniae. Infect Chemother. 2007. 39:65–70.

4. Brahmi N, Blel Y, Kouraichi N, Lahdhiri S, Thabet H, Hedhili A, Amamou M. Impact of ceftazidime restriction on gram-negative bacterial resistance in an intensive care unit. J Infect Chemother. 2006. 12:190–194.

5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. CLSI document. 2007. 7th. Wayne, PA: CLSI;M100–S17. .

6. Clinical and Laboratory Standards Institute. Methods for dilution Antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI document. 2006. 7th. Wayne, PA: CLSI;M7–A7. .

7. Schmitt J, Jacobs E, Schmidt H. Molecular characterization of extended-spectrum beta-lactamases in Enterobacteriaceae from patients of two hospitals in Saxony, Germany. J Med Microbiol. 2007. 56:241–249.

8. Dutour C, Bonnet R, Marchandin H, Boyer M, Chanal C, Sirot D, Sirot J. CTX-M-1, CTX-M-3, and CTX-M-14 beta-lactamases from Enterobacteriaceae isolated in France. Antimicrob Agents Chemother. 2002. 46:534–537.

TOOLS

Similar articles